The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-India's COVID vaccine wins over some sceptics after promising data

Thu, 04th Mar 2021 16:19

(Adds Zimbabwe approval for vaccine in paragraph 4)

By Krishna N. Das

NEW DELHI, March 4 (Reuters) - Indian doctors and
politicians on Thursday welcomed efficacy data for a
state-backed coronavirus vaccine that was given emergency
approval in January without the completion of a late-stage
trial, making people reluctant to receive the shot.

Government data shows https://dashboard.cowin.gov.in that
only 10% of about 13.3 million people immunised in India have
taken the COVAXIN shot, which was found to be 81% effective in
an interim analysis of the late-stage trial, its developer
Bharat Biotech said on Wednesday.

Any boost to the vaccine's acceptance in India, which on
Thursday reported the highest number of new COVID-19 cases in
five weeks, could also brighten its export prospects.

Bharat Biotech said 40 countries were interested in COVAXIN,
with Zimbabwe https://twitter.com/IndiainZimbabwe/status/1367431775002238976
on Thursday becoming the first country outside India to approve
it, according to the Indian embassy https://twitter.com/IndiainZimbabwe/status/1367445837731790848
there.

Many Indian doctors and opposition politicians had rejected
COVAXIN because it was approved by the drug regulator only on
the basis of data from intermediate trials. The regulator has
also authorised the use of the Oxford University/AstraZeneca
vaccine, marketed as Covishield in India, which was
found to be 70.42% effective based on overseas trials.

"Now that interim Phase III data are available for COVAXIN,
I can safely ask my father, who is more than 60 years of age and
a diabetic, to get it," said Nirmalya Mohapatra, a leader of an
association of doctors at New Delhi's Ram Manohar Lohia
Hospital, having previously publicly refused to take COVAXIN.

Rajib Dasgupta, chairperson of the Centre of Social Medicine
& Community Health at New Delhi's Jawaharlal Nehru University,
said the interim results were encouraging but that a
"well-rounded picture" would emerge only after a fuller
analysis.

Opposition lawmaker Shashi Tharoor welcomed the announcement
by Bharat Biotech, which plans to make 700 million doses a year.

"For those like me who were concerned that COVAXIN was being
deployed before its third phase trials were concluded, this is
good news indeed," he said on Twitter.

India reported 17,407 COVID-19 cases in the past 24 hours,
taking the total to 11.16 million. Deaths rose by 89 to 157,435.
(Reporting by Krishna N. Das; Additional reporting by Philip
George in Bengaluru; Editing by Simon Cameron-Moore and Nick
Macfie)

More News
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 17:22

UK's FTSE 100 pressured by stronger pound; miners climb

FTSE 100 flat, FTSE 250 up 0.2%

*

Read more
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more
2 Apr 2024 10:25

AstraZeneca and Daiichi make US progress with latest licence approvals

(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.

Read more
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.